This website is intended for UK patients who have been prescribed RYBELSUS® (semaglutide tablets).
Welcome to RYBELSUS® (semaglutide tablets)
This is not a real patient and is for illustrative purposes only.
Welcome to the RYBELSUS® UK Patient Website
Welcome! You are here either because you have been prescribed RYBELSUS® yourself, or you are a carer of someone who has been prescribed the medication.
This website has been developed by Novo Nordisk UK to provide a range of resources to support your use of RYBELSUS®.
Please note RYBELSUS® is undergoing a transition which will affect your RYBELSUS® tablets.
Learn more about the NEW Formulation of RYBELSUS® below and in our patient transition guide.
This information does not replace the Patient Information Leaflet, which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice.
For information on reporting side effects please see the bottom of this page.
In the links below you can access the RYBELSUS® Patient Information Leaflets, which can be found on the electronic Medicines Compendium (eMC)
Why have you been prescribed RYBELSUS®?
Having type 2 diabetes means that managing your blood sugar levels within a normal range is very important.
You and your healthcare professional have decided that RYBELSUS® is the appropriate medication to help you do this.
What is RYBELSUS® and what is it used for?
RYBELSUS® is a medicine containing the active substance semaglutide, which is used to lower blood glucose (sugar) levels in adults (18 years and older) with type 2 diabetes when diet and exercise is not enough. It can be used on its own when metformin (another medicine for diabetes) cannot be used, or in combination with other diabetes medicines, when the other medicines are not enough to control your blood sugar levels.
It is important that you continue with your diet and exercise plan as agreed with your doctor, pharmacist or nurse.
Your NEW RYBELSUS® tablets
RYBELSUS® is undergoing a transition which will affect your RYBELSUS® tablets.
We have developed a Patient Transition Guide to support you during the transition from the previous formulation of RYBELSUS® to the new formulation.
The new RYBELSUS® tablets have been improved to help your body absorb the medication more effectively than your previous RYBELSUS® tablets.
This means you can get similar results with a smaller dose and smaller tablet.
Learn more about the new formulation by viewing the RYBELSUS® patient transition guide here.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme
at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573).
Calls may be monitored for training purposes. By reporting side effects, you can help provide more information on the safety of this medicine.
See yellowcard.mhra.gov.uk for how to report side effects.